

- 45. (New) A vaccine that effectively treats cancer by stimulating or enhancing in a subject who is afflicted with cancer, production of an antibody which recognizes a ganglioside, comprising an amount of a ganglioside or an oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.--
- 46. (New) The vaccine of claim 44, wherein cells of the cancer have gangliosides on surfaces of cancerous cells.--
- 47. (New) The vaccine of claim 44, wherein gangliosides are found in the stroma of the cancer.--
- 48. (New) The vaccine of claim 44, wherein the cancer originates in epithelium.--
- 49  
--49. (New) The vaccine of claim 45, wherein gangliosides are found in the stroma of the cancer.--
- 50. (New) The vaccine of claim 45, wherein the cancer originates from epithelium.--
- 51. (New) The vaccine of claim 44, wherein the cancer originates from neuroectoderm.--
- 52. (New) The vaccine of claim 45, wherein the cancer originates from neuroectoderm.--
- 53. (New) The vaccine of claim 49, wherein the cancer is a melanoma.--

- 54. (New) The vaccine of claim 52, wherein the cancer is a melanoma.--
- 55. (New) A method for stimulating or enhancing in a subject production of antibodies which recognize a ganglioside comprising administering to the subject an effective dose of a vaccine comprising an amount of a ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein and an effective amount of adjuvant effective to stimulate or enhance antibody production in the subject.--
- 56. (New) The method of claim 55, wherein the ganglioside is GM2.--
- 57. (New) The method of claim 55, wherein the ganglioside is GD3.--
- 58. (New) A method for treating cancer in a subject afflicted with cancer comprising administering to the subject an effective dose of the vaccine of claim 45.--
- 59. (New) A method for preventing cancer in a subject susceptible to cancer comprising administering to the subject an effective dose of the vaccine of claim 44.--
- 60. (New) The method of claim 55, 58 or 59, wherein the vaccine comprises a ganglioside or oligosaccharide portion thereof is conjugated to Keyhole Limpet Hemocyanin or a derivative or Keyhole Limpet Hemocyanin and an adjuvant.--

B1  
cont

- 61. (New) The method of claim 60, wherein the adjuvant is QS-21.--
- 62. (New) The method of claim 58 or 59, wherein the gangliosides are found on cancer cell surfaces.--
- 63. (New) The method of claim 58 or 59, wherein the gangliosides are found in the stroma of the cancer.--
- 64. (New) The method of claim 58 or 59, wherein the cancer originates from epithelium.--
- 65. (New) The method of claim 58 or 59, wherein the cancer originates from neuroectoderm.--
- 66. (New) The method of claim 65, wherein the cancer is a melanoma.--
- 67. (New) The method of claim 55, wherein the administering comprises administering at two or more sites.--
- 68. (New) The method of claim 67, wherein the administering comprises administering at three sites.--

B'  
could

REMARKS

Claims 21-43 were pending in the subject application. With the amendments hereinabove, applicants canceled claims 21-43 without prejudice to applicants' right to pursue the subject matter of these claims in a divisional or continuation application. Applicants added new claims 44-68. Accordingly,